Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma
This is a Phase I, open-label, multi-dose trial to define the MTD and tolerability of a regimen including lenalidomide, dexamethasone, and intravenous SGN-40 in patients with relapsed multiple myeloma.
Multiple Myeloma
DRUG: SGN-40|DRUG: lenalidomide|DRUG: dexamethasone
Adverse events and lab abnormalities., Within 3 weeks of final infusion of SGN-40
Best clinical response, progression-free survival, and overall survival., Study duration|PK profile., Within 3 weeks of final infusion of SGN-40|Anti-drug antibody immune responses., Within 3 weeks of final infusion of SGN-40
This is a Phase I, open-label, multi-dose trial to define the MTD and tolerability of a regimen including lenalidomide, dexamethasone, and intravenous SGN-40 in patients with relapsed multiple myeloma.